Published in Women's Health Weekly, December 25th, 2003
1) Preclinical data suggesting that an investigational fully human monoclonal antibody, designated 18F1, that targets the Vascular Endothelial Growth Factor Receptor-1 (also known as VEGFR-1 or FLT-1) effectively blocked the binding of growth factors VEGF and Placental Growth Factor and inhibited tumor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly